BioSpace News Archive

Vaccitech plc today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection.

Q32 Bio and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease.

Lineage Cell Therapeutics, Inc. today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501.

Ocugen, Inc. today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber congenital amaurosis (LCA) with mutation(s) in the CEP290 gene.

Hoth Therapeutics, Inc. today announced that HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM) achieved positive preclinical results in a study sponsored by Hoth.

IMUNON, Inc. reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time.

Inspira™ Technologies OXY BHN Ltd. announced it had submitted its INSPIRA ART 100, a cardio-pulmonary bypass device, to the U.S. Food and Drug Administration (FDA) via the 510(k) pathway, with potential clearance expected during the first half of 2024.

New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemer.

Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to present a groundbreaking update on its latest scientific endeavor: